CalciMedica is trading at $0.93 (up 10.3%), extending a sharp multi-day rebound that followed positive regulatory news regarding its lead clinical program.
- The stock's momentum is driven by FDA alignment on the design and endpoints for a planned Phase 2b trial in acute pancreatitis.
- Shares have continued to climb despite broader biotech sector weakness, building on an initial 11% jump seen on July 29.
- Investors are responding to the clarified regulatory path, which provides a clearer timeline for the company's primary development goals.